Literature DB >> 29265421

Hidradenitis suppurativa treated with wide excision and second intention healing: a meaningful local cure rate after 253 procedures.

I E Deckers1, Y Dahi1, H H van der Zee1, E P Prens1.   

Abstract

BACKGROUND: Surgery is an important treatment modality for hidradenitis suppurativa (HS). Various methods of HS surgery have been described. Even though wide excision is a common surgical procedure for HS, data on the recurrence rate and patient satisfaction are scarce.
OBJECTIVE: To determine the recurrence rate and patient satisfaction of HS lesional wide excision (complete excision) with secondary intention healing.
METHODS: A single centre retrospective study. Hundred and twenty eligible patients were identified from our medical files, and an individualized questionnaire was sent.
RESULTS: Eighty-six patents responded to our questionnaire (71.7%). Of whom, 84 patients underwent in total 253 procedures. The mean follow-up time per procedure was 36.2 months. In 37.6% of the procedures, recurrence occurred within a mean follow-up period of 3 years (after a median of 6.0 months). Total remission of an anatomical area was achieved in 49% of the procedures, whereas natural disease progression occurred in 13%. The genital region was the most prone to recurrence. The majority of the patients were glad that they had undergone the procedure and would recommend the surgical procedure to other HS patients.
CONCLUSION: Lesional wide excision (complete excision) with secondary intention healing yields a meaningful local cure rate for HS and is well tolerated.
© 2017 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2018        PMID: 29265421     DOI: 10.1111/jdv.14770

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  7 in total

1.  The surgeon’s perspective: a retrospective study of wide local excisions taken to healthy subcutaneous fat in the management of advanced hidradenitis suppurativa

Authors:  Eran Shavit; Andrew Pawliwec; Afsaneh Alavi; Ralph George
Journal:  Can J Surg       Date:  2020-02-28       Impact factor: 2.089

2.  Factors influencing the local cure rate of hidradenitis suppurativa following wide local excision.

Authors:  Ledibabari M Ngaage; Yinglun Wu; Shealinna Ge; Selim Gebran; Fan Liang; Erin M Rada; Arthur J Nam; Ronald P Silverman; Yvonne M Rasko
Journal:  Int Wound J       Date:  2019-11-03       Impact factor: 3.315

Review 3.  Surgical Treatment in Hidradenitis Suppurativa.

Authors:  Ratnakar Shukla; Priyanka Karagaiah; Anant Patil; Katherine Farnbach; Alex G Ortega-Loayza; Thrasivoulos Tzellos; Jacek C Szepietowski; Mario Giulini; Hadrian Schepler; Stephan Grabbe; Mohamad Goldust
Journal:  J Clin Med       Date:  2022-04-21       Impact factor: 4.964

4.  Neoadjuvant Biologic Therapy in the Surgical Management of Patients with Hidradenitis Suppurativa: A Cohort Study.

Authors:  Luis Salvador-Rodriguez; Carlos Cuenca-Barrales; Salvador Arias-Santiago; Alejandro Molina-Leyva
Journal:  Acta Derm Venereol       Date:  2020-09-08       Impact factor: 3.875

5.  A Multicenter Comparison of Reconstruction Strategies after Wide Excision for Severe Axillary Hidradenitis Suppurativa.

Authors:  Zachri N Ovadja; Sophieke A W Bartelink; Annekatrien L van de Kar; Chantal M A M van der Horst; Oren Lapid
Journal:  Plast Reconstr Surg Glob Open       Date:  2019-08-05

6.  The role of negative-pressure wound therapy in the management of axillary hidradenitis suppurativa.

Authors:  Anne-Cecile Ezanno; Anne-Claire Fougerousse; Philippe Guillem
Journal:  Int Wound J       Date:  2021-09-29       Impact factor: 3.099

Review 7.  Outcomes and Reliability of Perforator Flaps in the Reconstruction of Hidradenitis Suppurativa Defects: A Systemic Review and Meta-Analysis.

Authors:  Camille Vaillant; Yanis Berkane; Elise Lupon; Michael Atlan; Pascal Rousseau; Alexandre G Lellouch; Jérôme Duisit; Nicolas Bertheuil
Journal:  J Clin Med       Date:  2022-09-30       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.